Objective: We observed an overall increase in the use of third- and fourth-generation cephalosporins after fluoroquinolone preauthorization was implemented. We examined the change in specific third- and fourth-generation cephalosporin use, and we sought to determine whether there was a consequent change in non-susceptibility of select Gram-negative bacterial isolates to these antibiotics.
Design: Retrospective quasi-experimental study.
Setting: Academic hospital.
Intervention: Fluoroquinolone preauthorization was implemented in the hospital in October 2005. We used interrupted time series (ITS) Poisson regression models to examine trends in monthly rates of ceftriaxone, ceftazidime, and cefepime use and trends in yearly rates of nonsusceptible isolates (NSIs) of select Gram-negative bacteria before (1998-2004) and after (2006-2016) fluoroquinolone preauthorization was implemented.
Results: Rates of use of ceftriaxone and cefepime increased after fluoroquinolone preauthorization was implemented (ceftriaxone RR, 1.002; 95% CI, 1.002-1.003; < .0001; cefepime RR, 1.003; 95% CI, 1.001-1.004; .0006), but ceftazidime use continued to decline (RR, 0.991, 95% CI, 0.990-0.992; < .0001). Rates of ceftazidime and cefepime NSIs of (ceftazidime RR, 0.937; 95% CI, 0.910-0.965, < .0001; cefepime RR, 0.937; 95% CI, 0.912-0.963; < .0001) declined after fluoroquinolone preauthorization was implemented. Rates of ceftazidime and cefepime NSIs of (ceftazidime RR, 1.116; 95% CI, 1.078-1.154; < .0001; cefepime RR, 1.198; 95% CI, 1.112-1.291; < .0001) and cefepime NSI of (RR, 1.169; 95% CI, 1.081-1.263; < .0001) were increasing before fluoroquinolone preauthorization was implemented but became stable thereafter: (ceftazidime RR, 0.987; 95% CI, 0.948-1.028; .531; cefepime RR, 0.990; 95% CI, 0.962-1.018; = .461) and (cefepime RR, 0.972; 95% CI, 0.939-1.006; = .100).
Conclusions: Fluoroquinolone preauthorization may increase use of unrestricted third- and fourth-generation cephalosporins; however, we did not observe increased antimicrobial resistance to these agents, especially among clinically important Gram-negative bacteria known for hospital-acquired infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/ice.2021.229 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antimicrobial Consumption and Resistance of Restricted Antibiotics in a Level III Government Hospital.
Acta Med Philipp
September 2024
Department of Pharmacy, Philippine General Hospital.
Objectives: The objectives of the study were to determine the antibiotic consumption of restricted antibiotics and to correlate this with resistance rate.
Methods: A retrospective review of pharmacy dispensing records was conducted in the adult internal medicine wards of a tertiary level teaching hospital in the Philippines between March 2019 to February 2020. Antibiotic consumption was determined using Defined Daily Dose (DDD) per 1000 patient-days (PD).
Understanding clinical implementation coordinators' experiences in deploying evidence-based interventions.
Am J Health Syst Pharm
February 2024
School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Purpose: The fluoroquinolone restriction for the prevention of Clostridioides difficile infection (FIRST) trial is a multisite clinical study in which sites carry out a preauthorization process via electronic health record-based best-practice alert (BPA) to optimize the use of fluoroquinolone antibiotics in acute care settings. Our research team worked closely with clinical implementation coordinators to facilitate the dissemination and implementation of this evidence-based intervention. Clinical implementation coordinators within the antibiotic stewardship team (AST) played a pivotal role in the implementation process; however, considerable research is needed to further understand their role.
View Article and Find Full Text PDFA Nonrestrictive Approach to Fluoroquinolone Stewardship at Two Community Hospitals.
Open Forum Infect Dis
August 2022
Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, California, USA.
Background: Fluoroquinolones are one of the most prescribed antimicrobials in the United States and have been increasingly used in inpatient and outpatient settings to treat various infectious diseases syndromes. Due to the unwanted collateral effects on antibiotic resistance, poor susceptibility rates among Gram-negative pathogens, and adverse effects, fluoroquinolones are often targeted by hospital antimicrobial stewardship programs to prevent overutilization. This study describes the association of nonrestrictive antimicrobial stewardship interventions at 2 nonacademic community hospitals on levofloxacin utilization, prescribing patterns on alternative antibiotics, and nonsusceptibility rates to levofloxacin.
View Article and Find Full Text PDFHow fluoroquinolone preauthorization affects third- and fourth-generation cephalosporin use and resistance in a large academic hospital.
Infect Control Hosp Epidemiol
July 2022
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama.
Objective: We observed an overall increase in the use of third- and fourth-generation cephalosporins after fluoroquinolone preauthorization was implemented. We examined the change in specific third- and fourth-generation cephalosporin use, and we sought to determine whether there was a consequent change in non-susceptibility of select Gram-negative bacterial isolates to these antibiotics.
Design: Retrospective quasi-experimental study.
The effectiveness of prescription support and treatment reporting system on the appropriate usage of oral third-generation cephalosporins.
J Infect Chemother
March 2021
Department of Pharmacy, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo, 180-8610, Japan. Electronic address:
Introduction: Preauthorization and prospective audit and feedback system are reported to be effective for the achievement of appropriate use of intravenous antimicrobials, but few reports on oral antimicrobials are available, especially for adults.
Methods: The prescription of oral third-generation cephalosporins (oral 3rd Ceph) for inpatients and outpatients from 2013 to 2018 was investigated. The study period was divided into three phases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!